Finance & Investment

Enterprises struggle to measure AI's bottom-line impact. One AWS partner is offering a funded, 30-day program to turn Amazon Q trials into hard numbers.

As rising fees and complex perks turn travel cards into 'coupon books,' a new free tool aims to help users reclaim value. What's the real strategic play?

A key regulatory win in Abu Dhabi opens a new international front for NeOnc's war on brain tumors, backed by novel science and significant insider buying.

A new real-time index from AI firm Quandri reveals a dramatic slowdown in home insurance premium increases, though relief is uneven across the country.

WesBanco's inclusion in the S&P SmallCap 600 isn't just a milestone; it's a playbook on strategic growth and a key signal for investors in a shifting market.

Gelteq aims to replace needles with its ingestible gel, targeting diabetes and more. But can it balance this lofty goal with near-term revenue and tight finances?

Deswell Industries reports lower fiscal 2026 sales, but a pivot to high-margin electronics and savvy investments paint a complex picture of resilience.

Wafra's third consecutive 'World's Best Islamic Fund Manager' award is more than a trophy; it's a barometer for the booming Shari'ah-compliant market.

A new partnership opens institutional private credit to thousands of advisors. But what are the real opportunities and hidden risks behind this "democratization"?

Rare complete responses in deadly pancreatic cancer hint at a powerful new synergy, but can Elicio Therapeutics secure the funding to prove its theory?

As giants rule the obesity market, small-cap MetaVia pitches a novel dual-agonist and a first-in-class MASH drug. Can its science win the day?

Glass House Brands follows a new playbook, splitting its business to chase a NYSE listing. Is this the key that unlocks institutional capital for the entire sector?

Toews Asset Management's new HRSK ETF launched with an innovative, tax-smart funding method and a responsive risk strategy, signaling a new era in financial engineering.

In Las Vegas, IQSTEL is on a mission to woo institutional investors. With a massive acquisition and a new buyback, can it fix its valuation problem?

Adaptive Biotechnologies' sophisticated convertible note offering isn't just about capital; it's a strategic de-risking of its finances to accelerate its fight against cancer.

The acquisition of Mainstream Renewable Power South Africa signals a major capital injection into the nation's strained grid, accelerating its pivot from coal.

A return to profit and a 4.6p special dividend signal success for Octopus AIM VCT. But a deeper look reveals a masterclass in strategic exits and a VCT sector at a crossroads.

A landmark deal between Trading Technologies and Kalshi is set to unlock prediction markets for institutional investors, leveraging advanced tools for a new era of risk management.

In a world of AI traders and endless data, EverForward's Brian Ferdinand argues that the key to success isn't more tech, but timeless human discipline.

A credit rating upgrade for GSL reveals a masterclass in strategic fleet management and financial discipline, offering a blueprint for resilience.